Cellomics has acquired Momentum Healthcare Ltd. of Southampton and Cardiff, UK. Momentum’s technology — a suite of software components to extract cellular knowledge from biological and chemical structure information — will be integrated into Cellomics’ technology platform.
Cellomics is developing a platform of screening tools and bioinformatics products to provide knowledge about cells and cellular functions. Its CellSpace Knowledge Miner monitors the research literature of molecular and cellular biology and stores information on intermolecular relationships. Cellomics said its Array- Scan high-content screening system is installed in nine of the top ten pharmaceutical companies in the world.
Due to a pre-IPO quiet period, Cellomics spokesman Drew Patrick was unable to provide further details on how the two companies’ technology platforms will be integrated. Patrick noted that the two companies were still working out the details of the acquisition, but said there were no layoffs planned at either company.
Ian Shaw, formerly CEO of Momentum, will serve as vice president of therapeutic discovery at Cellomics, while Mark Collins of Momentum will be senior director of pharmaceutical informatics. Both Shaw and Collins will be based at Cellomics’ corporate headquarters in Pittsburgh, Pa.
Patrick said Cellomics still intends to complete its initial public offering, which it postponed eight months ago, but is following a “market-driven time frame” at this time.